WO2000056292A3 - Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine - Google Patents

Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine Download PDF

Info

Publication number
WO2000056292A3
WO2000056292A3 PCT/EP2000/001930 EP0001930W WO0056292A3 WO 2000056292 A3 WO2000056292 A3 WO 2000056292A3 EP 0001930 W EP0001930 W EP 0001930W WO 0056292 A3 WO0056292 A3 WO 0056292A3
Authority
WO
WIPO (PCT)
Prior art keywords
6alkyl
hydroxy
halo
cyano
optionally substituted
Prior art date
Application number
PCT/EP2000/001930
Other languages
French (fr)
Other versions
WO2000056292A2 (en
Inventor
David John Heal
Sharon Lesley Smith
Original Assignee
Knoll Ag
David John Heal
Sharon Lesley Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag, David John Heal, Sharon Lesley Smith filed Critical Knoll Ag
Priority to MXPA01009386A priority Critical patent/MXPA01009386A/en
Priority to EP00916901A priority patent/EP1161244A2/en
Priority to JP2000606198A priority patent/JP2002539241A/en
Priority to AU38088/00A priority patent/AU3808800A/en
Priority to CA002365115A priority patent/CA2365115A1/en
Publication of WO2000056292A2 publication Critical patent/WO2000056292A2/en
Publication of WO2000056292A3 publication Critical patent/WO2000056292A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Abstract

A method of treating migraine comprising the administration of a therapeutically effective amount of a compound of formula (I) including pharmaceutically acceptable salts, solvates, racemates, enantiomers, diastereoisomers and mixtures thereof in which: R1 represents H or one of the following groups (optionally substituted with one or more of halo, cyano, hydroxy or amino): C1-6alkyl, C1-6alkoxy or C1-6alkanoyl; R2 and R3 independently represent H or one of the following groups (optionally substituted with one or more of halo, cyano, hydroxy or amino): C1-6alkyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkylthio, C1-6alkylsulphinyl, C1-6alkylsulphonyl or hydroxy; R4 and R5 independently represent H, C1-6alkyl or R4 and R5 combined together with the carbon atom to which they are attached represent C3-6cycloalkylidene (each alkyl or cycloalkylidene being optionally substituted with one or more of halo, cyano, hydroxy, amino or C1-6alkyl); and R6, R7 and R8 independently represent H, halo, hydroxy, mercapto, nitro, cyano or one of the following groups (optionally substituted with one or more of halo, cyano, hydroxy or amino; and any nitrogen atom being optionally substituted with one or more C1-6alkyl): C1-6alkyl, C1-6alkanoyl, C1-6alkoxy, C2-6alkoxycarbonyl, carboxy, C1-6alkanoyloxy, C1-6alkylthio, C1-6alkylsulphinyl, C1-6alkylsulphonyl, C1-6alkylsulphonylamino, sulphamoyl, carbamoyl, C2-6alkylcarbamoyl or C1-6alkanoylamino; to a mammal in need thereof.
PCT/EP2000/001930 1999-03-18 2000-03-06 Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine WO2000056292A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA01009386A MXPA01009386A (en) 1999-03-18 2000-03-06 Compounds for use in therapy.
EP00916901A EP1161244A2 (en) 1999-03-18 2000-03-06 Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine
JP2000606198A JP2002539241A (en) 1999-03-18 2000-03-06 Therapeutic compounds
AU38088/00A AU3808800A (en) 1999-03-18 2000-03-06 Compounds for use in therapy
CA002365115A CA2365115A1 (en) 1999-03-18 2000-03-06 Compounds for use in therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9906130.1A GB9906130D0 (en) 1999-03-18 1999-03-18 Compounds for use in therapy
GB9906130.1 1999-03-18

Publications (2)

Publication Number Publication Date
WO2000056292A2 WO2000056292A2 (en) 2000-09-28
WO2000056292A3 true WO2000056292A3 (en) 2001-04-05

Family

ID=10849803

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/001930 WO2000056292A2 (en) 1999-03-18 2000-03-06 Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine

Country Status (8)

Country Link
EP (1) EP1161244A2 (en)
JP (1) JP2002539241A (en)
CN (1) CN1350457A (en)
AU (1) AU3808800A (en)
CA (1) CA2365115A1 (en)
GB (1) GB9906130D0 (en)
MX (1) MXPA01009386A (en)
WO (1) WO2000056292A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914743D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
WO2020231723A1 (en) 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010521A1 (en) * 1993-10-13 1995-04-20 Knoll Ag Therapeutic agents
WO1996015782A1 (en) * 1994-11-18 1996-05-30 The General Hospital Corporation A method for treating vascular headaches
WO1998007724A1 (en) * 1996-08-23 1998-02-26 Knoll Aktiengesellschaft Process for the preparation of 7-alkoxyalkyl-1,2,4-triazolo[1,5-a] pyrimidine derivatives
WO2000056336A2 (en) * 1999-03-18 2000-09-28 Knoll Gmbh Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010521A1 (en) * 1993-10-13 1995-04-20 Knoll Ag Therapeutic agents
WO1996015782A1 (en) * 1994-11-18 1996-05-30 The General Hospital Corporation A method for treating vascular headaches
WO1998007724A1 (en) * 1996-08-23 1998-02-26 Knoll Aktiengesellschaft Process for the preparation of 7-alkoxyalkyl-1,2,4-triazolo[1,5-a] pyrimidine derivatives
WO2000056336A2 (en) * 1999-03-18 2000-09-28 Knoll Gmbh Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CUTRER, F. MICHAEL (1) ET AL: "The actions of valproate and neurosteroids in a model of trigeminal pain.", HEADACHE, (1996) VOL. 36, NO. 10, PP. 579-585., XP000957623 *
SMITH, S. L. (1) ET AL: "Demonstration of neuroprotection by the novel anticonvulsant, BTS 72 664, after permanent focal cerebral ischaemia in rats.", BRITISH JOURNAL OF PHARMACOLOGY, (JULY, 1998) VOL. 124, NO. PROC. SUPPL., PP. 50P. MEETING INFO.: MEETING OF THE BRITISH PHARMACOLOGICAL SOCIETY CHESTER, ENGLAND, UK APRIL 22-24, 1998 BRITISH PHARMACOLOGICAL SOCIETY., XP000957423 *
SMITH, S. L. (1) ET AL: "Improvement of functional deficit after permanent focal ischaemia in rats provided by the novel anticonvulsant, BTS 72 664.", BRITISH JOURNAL OF PHARMACOLOGY, (JULY, 1998) VOL. 124, NO. PROC. SUPPL., PP. 51P. MEETING INFO.: MEETING OF THE BRITISH PHARMACOLOGICAL SOCIETY CHESTER, ENGLAND, UK APRIL 22-24, 1998 BRITISH PHARMACOLOGICAL SOCIETY., XP000957422 *

Also Published As

Publication number Publication date
CA2365115A1 (en) 2000-09-28
EP1161244A2 (en) 2001-12-12
GB9906130D0 (en) 1999-05-12
JP2002539241A (en) 2002-11-19
CN1350457A (en) 2002-05-22
MXPA01009386A (en) 2004-03-19
WO2000056292A2 (en) 2000-09-28
AU3808800A (en) 2000-10-09

Similar Documents

Publication Publication Date Title
CA2341968A1 (en) Pyrrolobenzodiazepine compounds
TR200002191T2 (en) Potassium channel inhibitors
AU7578894A (en) Methods for inhibiting smooth muscle cell proliferation and restinosis
BG106586A (en) Pyrazolopyramidines as therapeutic agents
WO2002024635A3 (en) Aminoalcohol derivatives
CA2160447A1 (en) Amino(thio)ether derivatives
EP0638567A4 (en) Adenosine incorporation inhibitor.
MXPA96001371A (en) N-aryl [1, 2, 4]triazolo [1, 5-a]pyridine-2 -sulfonamide herbicides.
CA2290766A1 (en) Method of treating nitrate-induced tolerance
AP9701041A0 (en) Pyridylpyrrole compounds.
MY119321A (en) Substituted tetracyclic tetrahydrofuran derivatives
IL119207A0 (en) Treatment of tinnitus using neuroprotective agents
AP2000001900A0 (en) Halogeneted amidino amino acid derivatives useful as nitric oxide synthase inhibitors.
WO1998046576A3 (en) Halo-alkoxycarbonyl prodrugs
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
CA2322689A1 (en) Substituted bisindolymaleimides for the inhibition of cell proliferation
GB9310095D0 (en) Therapeutic compounds
WO2004014906A3 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
WO2002094770A3 (en) Aminoalcohol derivatives
WO2000056292A3 (en) Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine
MX2007003111A (en) Aminoalcohol derivatives.
WO2001080813A3 (en) Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
HK1041264A1 (en) Imidazole compounds and their use as adenosine deaminase inhibitors
EP1034783A4 (en) Amide derivatives
PL326554A1 (en) Derivatives of amine and thiourea and inhibitors of nitrogen oxide synthase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00807524.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2365115

Country of ref document: CA

Ref document number: 2365115

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 606198

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/009386

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000916901

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000916901

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09936773

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000916901

Country of ref document: EP